


PHARMACEUTICAL 2021

SYNLOGIC INC. Rank 203 of 409







PHARMACEUTICAL 2021

SYNLOGIC INC. Rank 203 of 409



The relative strengths and weaknesses of SYNLOGIC INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SYNLOGIC INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 61% points. The greatest weakness of SYNLOGIC INC. is the variable Research and Development, reducing the Economic Capital Ratio by 111% points.

The company's Economic Capital Ratio, given in the ranking table, is -132%, being 223% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	106,846
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,301
Liabilities, Non-Current	20,404
Other Assets	26,218
Other Compr. Net Income	-96
Other Expenses	0
Other Liabilities	0
Other Net Income	1,293
Property and Equipment	10,776
Research and Development	47,474
Revenues	545
Selling, General and Administrative Expense	13,537

Output Variable	Value in 1000 USD
Assets	143,840
Liabilities	28,705
Expenses	61,011
Stockholders Equity	115,135
Net Income	-59,173
Comprehensive Net Income	-59,221
Economic Capital Ratio	-132%